Insider Trading Alert - IVR, DXCM, VR, CLX And APO Traded By Insiders

Kahn Barbara who is Director at DexCom sold 1,500 shares at $32.63 on Dec. 6, 2013. Following this transaction, the Director owned 49,263 shares meaning that the stake was reduced by 2.95% with the 1,500-share transaction.

The shares most recently traded at $34.58, up $1.95, or 5.65% since the insider transaction. Historical insider transactions for DexCom go as follows:

4-Week # shares sold: 46,568

12-Week # shares sold: 46,568

24-Week # shares sold: 46,568

The average volume for DexCom has been 619,200 shares per day over the past 30 days. DexCom has a market cap of $2.5 billion and is part of the health care sector and health services industry. Shares are up 154.97% year-to-date as of the close of trading on Friday.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems. Currently there are 8 analysts that rate DexCom a buy, no analysts rate it a sell, and 5 rate it a hold.